Cargando…

Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer

BACKGROUND: As a type of new targets for prognosis of malignancies, long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcription 1) is associated with proliferation and metastatic abilities of several malignancies. However, its relations to development and migration of triple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiping, Zhang, Bo, Chen, Shifeng, Yang, Feijiang, Yu, Hongjian, Yang, Qihui, Cheng, Binbin, Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788637/ https://www.ncbi.nlm.nih.gov/pubmed/29416769 http://dx.doi.org/10.18632/oncotarget.23370

Ejemplares similares

Research progresses in roles of LncRNA and its relationships with breast cancer
por: Bin, Xu, et al.
Publicado: (2018)

Discussion of relationships among changes of pathological indicators, postoperative lymphedema of the upper limb, and prognosis of patients with breast cancer
por: Zhang, Xiping, et al.
Publicado: (2019)

New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer
por: Fu, Yeqin, et al.
Publicado: (2023)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
por: Bryan, Sarah, et al.
Publicado: (2021)

MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer
por: Turco, Chiara, et al.
Publicado: (2022)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Genomic Insights into Triple-Negative and HER2-Positive Breast Cancers Using Isogenic Model Systems
por: Mudvari, Prakriti, et al.
Publicado: (2013)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

JAG1 enhances angiogenesis in triple-negative breast cancer through promoting the secretion of exosomal lncRNA MALAT1
por: Liu, Junping, et al.
Publicado: (2022)

MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer
por: Mekky, Radwa Y., et al.
Publicado: (2023)

Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells
por: Yi, Huimei, et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
por: Altundag, Kadri
Publicado: (2017)

Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
por: Gupta, Ishita, et al.
Publicado: (2020)

Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines
por: Thongchot, Suyanee, et al.
Publicado: (2021)

Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
por: Wu, Xiaofan, et al.
Publicado: (2022)

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
por: Abdullah, Mashan L., et al.
Publicado: (2018)

Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
por: Hu, Xi′e, et al.
Publicado: (2023)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Triple-negative and triple-positive breast cancer cells reciprocally control their growth and migration via the S100A4 pathway
por: Dukhanina, Elena A., et al.
Publicado: (2022)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Hoogsteen-position pyrimidines promote the stability and function of the MALAT1 RNA triple helix
por: Brown, Jessica A., et al.
Publicado: (2016)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
por: Onesti, Concetta Elisa, et al.
Publicado: (2018)

HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells
por: Wu, Xuehong, et al.
Publicado: (2022)

A feedback loop between lncRNA MALAT1 and DNMT1 promotes triple-negative breast cancer stemness and tumorigenesis
por: Hu, Yu, et al.
Publicado: (2023)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

CTSL, a prognostic marker of breast cancer, that promotes proliferation, migration, and invasion in cells in triple-negative breast cancer
por: Zhang, Lianmei, et al.
Publicado: (2023)

BCL11A confers cell invasion and migration in androgen receptor-positive triple-negative breast cancer
por: Wang, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_stqcftad0tp32uot4gg2b7gf17